A 17% increase in net profit after tax (npat) to A$1.94 billion ($2.07b) for the six months to December 2023 has done little to slow the slide in CSL’s share price following an announcement yesterday that a new heart drug failed its trial.
Yesterday, A$7b was wiped off the market cap of the
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
